Provenance Record

Well-structured 902-word News article on Xenon's azetukalner Phase 3 results presented at AAN 2026. Covers trial design, efficacy data, mechanism of action, safety profile, regulatory context, and unmet need with appropriate depth. The historical context on ezogabine's withdrawal and how azetukalner addresses those safety signals is a strong editorial addition.

3 sources read. (1) GlobeNewswire Xenon press release — confirmed: 53.2% / 34.5% / 10.4% seizure reduction figures; placebo-adjusted 42.7pp effect; 380 patients enrolled; ~5 prior ASMs; ~12.75 seizures/month baseline; 50% responder rate (higher dose) vs 21% placebo; >6% complete seizure control vs <1% placebo; 90.9% reduction at month 48 from 131 long-term participants; 38.2% seizure freedom (≥12 consecutive seizure-free months); 25.2% maintained ≥24 months; dizziness 20.5% vs 3.2%; 775+ patient-years; Q3 2026 NDA target; no titration required; 90%/84% survey figures. All major facts confirmed verbatim. (2) BioPharma Dive — confirmed: Paul Matteis (Stifel analyst) quotes 'a home run' and 'way above investor expectations'; ~50% stock rise on top-line data day in March. (3) PubMed 33722992 — confirmed: drug-resistant epilepsy prevalence 36.3% in clinic-based cohorts (article states 'approximately 36 percent'); meta-regression confirmed higher prevalence in focal epilepsy vs generalized. All three sources confirmed.

All quantitative claims verified against sources. The 36% figure is correctly rounded from 36.3% and accurately attributed to the PubMed systematic review. The article correctly notes nearly 40% of X-TOLE2 participants had taken cenobamate (39% confirmed in press release) and 19% had stopped it prior to enrollment. No hallucinated quotes or misattributed figures found.

Approve. Technically accurate News article with all three sources confirmed. Quantitative trial data, analyst commentary, and epidemiological statistics all verified. Safety section contextualizing the ezogabine withdrawal adds genuine editorial value.